ED

Eric Dai

Investor at Dimension

San Francisco, California

Overview 

Eric Dai is an Investor at Dimension focused on Life Sciences and Technology in San Francisco, California. With a background in Biomedical Engineering and experience at top organizations like Andreessen Horowitz and the U.S. Department of Energy, Eric has excelled in roles ranging from Bio+Health Deal Analyst to Program Coordinator, showcasing his expertise in biotech and health IT sectors. Eric's career highlights include serving as a Bio+Health Deal Analyst at Andreessen Horowitz and founding Penn Bio Launch as Co-Managing Director, demonstrating his ability to excel in investment analysis and entrepreneurial ventures within the biotech industry.

Work Experience 

  • Stealth

    2025 - Current

  • Investment Team

    2023 - 2024

    Investing in founders pushing the frontier of tech and life sciences. Fund 1: $350M Fund 2: $500M

Dimension Capital is a venture capital firm that prefers to invest in various industries.

  • Investment Team

    2022 - 2023

    a16z Bio Fund IV $1.5B Vehicle for Early and Growth Stage Bio+Health Startups

Andreessen Horowitz is a stage-agnostic venture capital firm with assets under management across multiple funds.

  • PhD Student in Bioengineering, Mauck Lab

    2016 - 2022

    (On Leave, All But Dissertation) Stem Cell Mechanobiology/Engineering with Rob Mauck

  • Teaching Assistant

    2018 - 2021

    TA for MSE 496 Senior Design with Vanessa Chan TA for BE 306 Cellular Engineering with Daniel Hammer

  • Venture Associate

    2021 - 2022

    Petri/Pillar VC is a new approach for funding formation-stage startups at the intersection of biology and engineering. Created by the leaders behind iconic companies like Twist Bioscience, Ginkgo Bioworks, Beyond Meat, Exact Sciences, and many more.

Pillar VC invests in seed-stage companies, supporting unstoppable founders with capital, connections, coaching, and peer support.

  • Co-Founder, Co-Managing Director

    2021 - 2022

    Bio Launch supports venture formation from biotechnologies at the University of Pennsylvania, the Wistar Institute, and CHOP. Merged into Nucleate to form Nucleate Philadelphia.

  • Program Coordinator at the DOE Office of Technology Transitions

    2021 - 2022

    Cleantech Commercialization

US Department of Energy is a government administration that regulates energy policy, research, and development.

  • Biotech Correspondent

    2021 - 2022

    Reported on leading startups in mRNA engineering, nucleic acid delivery and more

  • Research Assistant

    2011 - 2012

    Particle Physics

Articles About Eric

Relevant Websites